Europe — EMA

Opdivo (Nivolumab)

Request sourcing

Pack/s

What is Nivolumab?

Nivolumab, the active ingredient in Opdivo, is a monoclonal antibody presented as a 240 mg/10 ml vial for intravenous infusion use. It is indicated for the treatment of various cancers in adult patients. GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

What is Nivolumab used for?

Opdivo is a checkpoint inhibitor that targets the PD‑1 pathway and is used in several oncology indications. - Melanoma: Improves survival in patients with unresectable or metastatic disease. - Non‑small cell lung cancer (NSCLC): Extends the overall duration of response and progression‑free survival. - Renal cell carcinoma (RCC): Provides durable long‑term benefits in advanced RCC. - Classical Hodgkin lymphoma: Offers a treatment option for relapsed or after ‑ c . - Head‑and‑neck squamous cell carcinoma : -

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →